Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study.

被引：0
|
作者：
Bartlett, Nancy
Brice, Pauline
Chen, Robert W.
Fanale, Michelle A.
Gopal, Ajay K.
Matous, Jeffrey
Rosenblatt, Joseph David
Grove, Laurie E.
Forero-Torres, Andres
机构：
[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[2] Hosp Saint Louis, Paris, France
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Seattle Genet Inc, Bothell, WA USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8027
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sezary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis
    Behle, Valeria
    Von Braunmuehl, Tanja
    Sayehli, Cyrus
    Gesierich, Anja
    Goebeler, Matthias
    Geissinger, Eva
    Wobser, Marion
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 973 - 975
  • [32] A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
    Jacobsen, Eric D.
    Advani, Ranjana H.
    Oki, Yasuhiro
    Sharman, Jeff
    Horwitz, Steven M.
    Forero-Torres, Andres
    O'Connor, Owen A.
    Shustov, Andrei R.
    Siddiqi, Tanya
    Grove, Laurie E.
    Bartlett, Nancy L.
    BLOOD, 2012, 120 (21)
  • [33] Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma
    Hirai, Yoji
    Sakurai, Jun
    Yoshida, Shiho
    Kikuchi, Takashi
    Mitsuhashi, Toshiharu
    Miyake, Tomoko
    Fujimura, Taku
    Abe, Riichiro
    Fujikawa, Hiroki
    Boki, Hikari
    Suga, Hiraku
    Shibata, Sayaka
    Miyagaki, Tomomitsu
    Shimauchi, Takatoshi
    Kiyohara, Eiji
    Kawakami, Yoshio
    Morizane, Shin
    JOURNAL OF DERMATOLOGY, 2024, 51 (08): : 1037 - 1049
  • [34] A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma
    Park, Silvia
    Kim, Seok Jin
    Hong, Jung Yong
    Yoon, Dok Hyun
    Kim, Jin Seok
    Kang, Hye Jin
    Eom, Hyeon-Seok
    Lee, Mark Hong
    Suh, Cheolwon
    Kim, Won Seog
    BLOOD, 2017, 130
  • [35] Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation
    Rothe, Achim
    Sasse, Stephanie
    Goergen, Helen
    Eichenauer, Dennis A.
    Lohri, Andreas
    Jaeger, Ulrich
    Bangard, Christopher
    Engert, Andreas
    BLOOD, 2012, 120 (21)
  • [36] CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
    Han, Tae H.
    Gopal, Ajay K.
    Ramchandren, Radhakrishnan
    Goy, Andre
    Chen, Robert
    Matous, Jeffrey V.
    Cooper, Maureen
    Grove, Laurie E.
    Alley, Stephen C.
    Lynch, Carmel M.
    O'Connor, Owen A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (08): : 866 - 877
  • [37] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
    Chen, W.
    Nathwani, N.
    Forman, S.
    Popplewell, L.
    Krishnan, A.
    Gomez, C.
    Karanes, C.
    Smith, E.
    Farol, L.
    Thomas, S.
    Kim, Y.
    HAEMATOLOGICA, 2012, 97 : 81 - 82
  • [38] Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin
    Popadic, Svetlana
    Lekic, Branislav
    Tanasilovic, Srdjan
    Bosic, Martina
    Nikolic, Milos
    DERMATOLOGIC THERAPY, 2020, 33 (01)
  • [39] A pilot study of weekly brentuximab vedotin in patients with CD30+malignancies resistant to brentuximab vedotin every 3 weeks
    Poston, Jacqueline N.
    Fromm, Jonathan R.
    Rasmussen, Heather A.
    Shustov, Andrei R.
    Libby, Edward N., III
    Smith, Stephen D.
    Gooley, Ted
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 159 - 162
  • [40] A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+Malignancies Resistant to Every 3 Week Brentuximab Vedotin
    Poston, Jacqueline N.
    Fromm, Jonathan R.
    Rasmussen, Heather A.
    Shustov, Andrei R.
    Libby, Edward N., III
    Smith, Stephen D.
    Gooley, Ted
    Gopal, Ajay K.
    BLOOD, 2017, 130
12345